Patent Law Weblog
recent posts
- Apple v. Squires: USPTO Director Has Unlimited Discretion on IPR Institution
- The Ghost in the Machine: Why GenAI Can Be Both a Brilliant Researcher and a Terrible Advocate
- Bayer Files Suit Against Trio of COVID-19 Vaccine Makers
- Allen v. Cooper (4th Cir. 2026)
- To Require an Inventor ID, or Not to Require an Inventor ID – That Is the Question
about
Month: June 2007
-
By Sherri Oslick — On Wednesday, Amgen Inc. of Thousand Oaks, CA announced that it would acquire drug company Alantos Pharmaceuticals of Cambridge, MA for $300 million cash. Alantos is a private company developing small molecule drugs for diabetes and inflammatory diseases. Following acquisition, Alantos will be a wholly owned subsidiary of Amgen.…
-
By Jason Derry — GenomeQuest, Inc. has announced that ARYx Therapeutics has signed on to use its GenomeQuest search and analysis application. As previously discussed on Patent Docs, GenomeQuest is a bioinformatics company that provides web-enabled applications for genetic sequence searching and analysis. ARYx is a pharmaceutical research and development company that uses…
-
By Kevin E. Noonan — The comparative effectiveness of two Genentech drugs, Lucentis® and Avastin®, for the treatment of age-related macular degeneration (AMD) is currently the subject of a study by the National Eye Institutes (NEI) of the National Institutes of Health. The reason: the cost of Avastin® treatment (an off-label use, since…
-
By Christopher P. Singer — The biotechnology, chemical, and pharmaceutical technology groups at the U.S. Patent Office will hold their quarterly customer partnership meeting on June 13, 2007. The meeting can be attended either live at the PTO or via the web. The topics listed on the agenda for the day-long meeting include…
-
By Sherri Oslick — On Monday, Amgen Inc. of Thousand Oaks, CA announced that it would acquire drug company Ilypsa, Inc. of Santa Clara, CA for $420 million cash. Ilypsa, formerly Symyx Therapeutics, is a private company developing non-absorbed, GI based drugs for phosphate, potassium, and sodium management in patients with chronic kidney…
-
Federal Circuit Upholds Liability And Damages in Genetically Modified Soybean Case By Sherri Oslick — Monsanto holds two patents related to its Roundup Ready technology: U.S. Patent No. 5,633,435 (RE39,247) and 5,352,605 [NB: Monsanto has asserted these two patents against nine farmers in the last five months.] Genetically modified Roundup Ready seeds yield…
-
By Christopher P. Singer — Last Thursday, the Biotechnology Industry Organization (BIO) published a white paper entitled: "The Myth of the Anticommons." The paper, authored by Dr. Ted Buckley (BIO Director of Economic Policy), asserts that there is a lack of any strong theoretical or empirical data which supports the theory of the…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring. Takeda Pharmaceutical Company Ltd. et. al. v. Teva Pharmaceuticals USA Inc. et. al.1:07-cv-00331; filed May 25, 2007 in the District Court of…
-
June 7, 2007 – "Biotechnology and the Law: A Primer" – Part II (ABA CLE) June 13, 2007 – "The Scope and Implications of the Supreme Court's Ruling in KSR v. Teleflex on the Doctrine of Patent Obviousness" (Practising Law Institute) June 21-22, 2007 – Technology IP Due Diligence Conference (American Conference Institute) – San…
-
The Institute of Continuing Legal Education (ICLE) will be holding its 33rd Annual Intellectual Property Law Summer Institute on July 12-14, 2007 on Mackinac Island in Michigan. The Institute, which is being co-sponsored by the Intellectual Property Law Section of the State Bar of Michigan, will provide information regarding the latest developments in patent, trademark,…
Patent Docs 